NCT07152405View on ClinicalTrials.gov

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

490

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Gastric or Gastro-esophageal Junction Adenocarcinoma
Interventions
DRUG

BL-M07D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Investigator's choice of chemotherapy

Administration by intravenous infusion for a cycle of 2 or 3 or 4 weeks.

Trial Locations (2)

Unknown

Harbin Medical University Cancer Hospital, Harbin

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY